Diagnostic Criteria and Clinical Outcomes in Sarcopenia Research: A Literature Review

Alex Han, Steven L Bokshan, Stephen E Marcaccio, J Mason DePasse, Alan H Daniels, Alex Han, Steven L Bokshan, Stephen E Marcaccio, J Mason DePasse, Alan H Daniels

Abstract

By the sixth decade of life, nearly one quarter of the population has substantial muscle atrophy, or sarcopenia. Despite the creation of a standardized definition of sarcopenia by the European Working Group on Sarcopenia in Older People, variability may exist in the diagnostic criteria utilized for clinical sarcopenia research. The primary objectives of this review were to characterize diagnostic criteria used for measurement of sarcopenia in original studies, and to describe associations between sarcopenia and important clinical outcomes. We performed a literature review of the term "sarcopenia" in PubMed. Inclusion criteria were English language, original data, a clear and specific definition for diagnosing sarcopenia, and the analysis of sarcopenia's effect on a clinical outcome. A total of 283 studies met inclusion criteria. More than half of the included sarcopenia investigations were level IV studies (54.1%), while 43.1% provided level II evidence. Under one third (27.6%) of studies examined sarcopenia with regard to surgical outcomes. In terms of diagnostic criteria for sarcopenia, 264 (93.3%) studies used measures of skeletal muscle mass, with dual energy X-ray absorptiometry (DEXA) being the most common modality (43.6%). Sarcopenia was found to be a consistent predictor of chronic disease progression, all-cause mortality, poorer functional outcomes, and postoperative complications. In conclusion, there is substantial evidence that sarcopenia impacts both medical and surgical outcomes. However, current research has utilized heterogeneous diagnostic criteria for sarcopenia. Further efforts to standardize the modalities used to diagnose sarcopenia in clinical research and practice will help strengthen our ability to study this important phenomenon.

Keywords: aging; atrophy; muscle mass; review; sarcopenia.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of publications meeting inclusion criteria based on a PubMed search of the term “sarcopenia” with the level of evidence breakdown of the resulting studies.
Figure 2
Figure 2
Distribution of included studies: surgical, medical, and population-based studies.

References

    1. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., Boirie Y., Cederholm T., Landi F., Martin F.C., Michel J.-P., Rolland Y., Schneider S.M., et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–423. doi: 10.1093/ageing/afq034.
    1. Melton L.J., Khosla S., Crowson C.S., O’Connor M.K., O’Fallon W.M., Riggs B.L. Epidemiology of sarcopenia. J. Am. Geriatr. Soc. 2000;48:625–630.
    1. Peterson S.J., Braunschweig C.A. Prevalence of sarcopenia and associated outcomes in the clinical setting. Nutr. Clin. Pract. 2016;31:40–48. doi: 10.1177/0884533615622537.
    1. Marty E., Liu Y., Samuel A., Or O., Lane J. A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease. Bone. 2017;105:276–286. doi: 10.1016/j.bone.2017.09.008.
    1. Kang S.H., Park J.W., Yoon K.W., Do J.Y. Limb/trunk lean mass ratio as a risk factor for mortality in peritoneal dialysis patients. J. Ren. Nutr. 2013;23:315–323. doi: 10.1053/j.jrn.2012.09.004.
    1. Huillard O., Mir O., Peyromaure M., Tlemsani C., Giroux J., Boudou-Rouquette P., Ropert S., Delongchamps N.B., Zerbib M., Goldwasser F. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br. J. Cancer. 2013;108:1034–1041. doi: 10.1038/bjc.2013.58.
    1. Sharma P., Zargar-Shoshtari K., Caracciolo J.T., Fishman M., Poch M.A., Pow-Sang J., Sexton W.J., Spiess P.E. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol. Oncol. 2015;33:339e17–339e23. doi: 10.1016/j.urolonc.2015.01.011.
    1. Merli M., Giusto M., Lucidi C., Giannelli V., Pentassuglio I., Di Gregorio V., Lattanzi B., Riggio O. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: Results of a prospective study. Metab. Brain Dis. 2013;28:281–284. doi: 10.1007/s11011-012-9365-z.
    1. Mir O., Coriat R., Blanchet B., Durand J.-P., Boudou-Rouquette P., Michels J., Ropert S., Vidal M., Pol S., Chaussade S., et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE. 2012;7:e37563. doi: 10.1371/journal.pone.0037563.
    1. Cousin S., Hollebecque A., Koscielny S., Mir O., Varga A., Baracos V.E., Soria J.C., Antoun S. Low skeletal muscle is associated with toxicity in patients included in phase I. trials. Investig. New Drugs. 2014;32:382–387. doi: 10.1007/s10637-013-0053-6.
    1. Prado C.M.M., Baracos V.E., McCargar L.J., Reiman T., Mourtzakis M., Tonkin K., Mackey J.R., Koski S., Pituskin E., Sawyer M.B. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 2009;15:2920–2926. doi: 10.1158/1078-0432.CCR-08-2242.
    1. Tan B.H.L., Birdsell L.A., Martin L., Baracos V.E., Fearon K.C.H. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res. 2009;15:6973–6979. doi: 10.1158/1078-0432.CCR-09-1525.
    1. Han K., Park Y.M., Kwon H.S., Ko S.H., Lee S.H., Yim H.W., Lee W.C., Park Y.G., Kim M.K., Park Y.M. Sarcopenia as a determinant of blood pressure in older Koreans: Findings from the Korea National Health and Nutrition Examination Surveys (KNHANES) 2008–2010. PLoS ONE. 2014;9:e86902. doi: 10.1371/journal.pone.0086902.
    1. Baek S.J., Nam G.E., Han K.D., Choi S.W., Jung S.W., Bok A.R., Kim Y.H., Lee K.S., Han B.D., Kim D.H. Sarcopenia and sarcopenic obesity and their association with dyslipidemia in Korean elderly men: The 2008-2010 Korea National Health and Nutrition Examination Survey. J. Endocrinol. Investig. 2014;37:247–260. doi: 10.1007/s40618-013-0011-3.
    1. Fulster S., Tacke M., Sandek A., Ebner N., Tschope C., Doehner W., Anker S.D., von Haehling S. Muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure (SICA-HF) Eur. Heart J. 2013;34:512–519. doi: 10.1093/eurheartj/ehs381.
    1. Narumi T., Watanabe T., Kadowaki S., Takahashi T., Yokoyama M., Kinoshita D., Honda Y., Funayama A., Nishiyama S., Takahashi H., et al. Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure. Eur. J. Intern. Med. 2015;26:118–122. doi: 10.1016/j.ejim.2015.01.008.
    1. Sheean P.M., Peterson S.J., Gomez Perez S., Troy K.L., Patel A., Sclamberg J.S., Ajanaku F.C., Braunschweig C.A. The prevalence of sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography and subjective global assessment. JPEN J. Parenter. Enteral Nutr. 2014;38:873–879. doi: 10.1177/0148607113500308.
    1. Jeon Y.K., Shin M.J., Kim M.H., Mok J.H., Kim S.S., Kim B.H., Kim S.-J., Kim Y.K., Chang J.H., Shin Y.B., et al. Low pulmonary function is related with a high risk of sarcopenia in community-dwelling older adults: The Korea National Health and Nutrition Examination Survey (KNHANES) 2008–2011. Osteoporos. Int. 2015;26:2423–2429. doi: 10.1007/s00198-015-3152-8.
    1. Cosquéric G., Sebag A., Ducolombier C., Thomas C., Piette F., Weill-Engerer S. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br. J. Nutr. 2006;96:895–901. doi: 10.1017/BJN20061943.
    1. Batsis J.A., Mackenzie T.A., Barre L.K., Lopez-Jimenez F., Bartels S.J. Sarcopenia, sarcopenic obesity and mortality in older adults: Results from the National Health and Nutrition Examination Survey III. Eur. J. Clin. Nutr. 2014;68:1001–1007. doi: 10.1038/ejcn.2014.117.
    1. Chan O.Y.A., van Houwelingen A.H., Gussekloo J., Blom J.W., den Elzen W.P.J. Comparison of quadriceps strength and handgrip strength in their association with health outcomes in older adults in primary care. Age (Dordr) 2014;36:9714. doi: 10.1007/s11357-014-9714-4.
    1. Janssen I., Shepard D.S., Katzmarzyk P.T., Roubenoff R. The healthcare costs of sarcopenia in the United States. J. Am. Geriatr. Soc. 2004;52:80–85. doi: 10.1111/j.1532-5415.2004.52014.x.
    1. Kirk P.S., Friedman J.F., Cron D.C., Terjimanian M.N., Wang S.C., Campbell D.A., Englesbe M.J., Werner N.L. One-year postoperative resource utilization in sarcopenic patients. J. Surg. Res. 2015;199:51–55. doi: 10.1016/j.jss.2015.04.074.
    1. Du Y., Karvellas C.J., Baracos V., Williams D.C., Khadaroo R.G., Acute Care and Emergency Surgery (ACES) Group Sarcopenia is a predictor of outcomes in very elderly patients undergoing emergency surgery. Surgery. 2014;156:521–527. doi: 10.1016/j.surg.2014.04.027.
    1. Reisinger K.W., van Vugt J.L.A., Tegels J.J.W., Snijders C., Hulsewé K.W.E., Hoofwijk A.G.M., Stoot J.H., Von Meyenfeldt M.F., Beets G.L., Derikx J.P.M., et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann. Surg. 2015;261:345–352. doi: 10.1097/SLA.0000000000000628.
    1. Miyamoto Y., Baba Y., Sakamoto Y., Ohuchi M., Tokunaga R., Kurashige J., Hiyoshi Y., Iwagami S., Yoshida N., Yoshida M., et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann. Surg. Oncol. 2015;22:2663–2668. doi: 10.1245/s10434-014-4281-6.
    1. Englesbe M.J., Patel S.P., He K., Lynch R.J., Schaubel D.E., Harbaugh C., Holcombe S.A., Wang S.C., Segev D.L., Sonnenday C.J. Sarcopenia and mortality after liver transplantation. J. Am. Coll. Surg. 2010;211:271–278. doi: 10.1016/j.jamcollsurg.2010.03.039.
    1. Fujiwara N., Nakagawa H., Kudo Y., Tateishi R., Taguri M., Watadani T., Nakagomi R., Kondo M., Nakatsuka T., Minami T., et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J. Hepatol. 2015;63:131–140. doi: 10.1016/j.jhep.2015.02.031.
    1. Otsuji H., Yokoyama Y., Ebata T., Igami T., Sugawara G., Mizuno T., Nagino M. Preoperative sarcopenia negatively impacts postoperative outcomes following major hepatectomy with extrahepatic bile duct resection. World J. Surg. 2015;39:1494–1500. doi: 10.1007/s00268-015-2988-6.
    1. Iolascon G., Giamattei M.T., Moretti A., Di Pietro G., Gimigliano F., Gimigliano R. Sarcopenia in women with vertebral fragility fractures. Aging Clin. Exp. Res. 2013;25(Suppl. 1):S129–S131. doi: 10.1007/s40520-013-0102-1.
    1. Lee S., Kim T.-N., Kim S.-H. Sarcopenic obesity is more closely associated with knee osteoarthritis than is nonsarcopenic obesity: A cross-sectional study. Arthritis Rheum. 2012;64:3947–3954. doi: 10.1002/art.37696.
    1. Fukushima H., Yokoyama M., Nakanishi Y., Tobisu K., Koga F. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS ONE. 2015;10:e0115895. doi: 10.1371/journal.pone.0115895.
    1. Kuroki L.M., Mangano M., Allsworth J.E., Menias C.O., Massad L.S., Powell M.A., Mutch D.G., Thaker P.H. Pre-operative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer. Ann. Surg. Oncol. 2015;22:972–979. doi: 10.1245/s10434-014-4040-8.
    1. Chamchod S., Fuller C.D., Grossberg A.J. (P091) sarcopenia/cachexia is associated with reduced survival and locoregional control in head and neck cancer patients receiving radiotherapy: Results from quantitative imaging analysis of lean body mass. Oncology (Williston Park NY) 2015;29:205153.
    1. Su J., Ekman C., Oskolkov N., Lahti L., Ström K., Brazma A., Groop L., Rung J., Hansson O. A novel atlas of gene expression in human skeletal muscle reveals molecular changes associated with aging. Skelet. Muscle. 2015;5:1–12. doi: 10.1186/s13395-015-0059-1.
    1. Roubenoff R., Hughes V.A. Sarcopenia: Current concepts. J. Gerontol. A Biol. Sci. Med. Sci. 2000;55:M716–M724. doi: 10.1093/gerona/55.12.M716.
    1. Rubbieri G., Mossello E., Di Bari M. Techniques for the diagnosis of sarcopenia. Clin. Cases Miner. Bone Metab. 2014;11:181–184. doi: 10.11138/ccmbm/2014.11.3.181.
    1. Ingenbleek Y., Bernstein L.H. Plasma transthyretin as a biomarker of lean body mass and catabolic states. Adv. Nutr. 2015;6:572–580. doi: 10.3945/an.115.008508.
    1. Narici M.V., Maffulli N. Sarcopenia: Characteristics, mechanisms and functional significance. Br. Med. Bull. 2010;95:139–159. doi: 10.1093/bmb/ldq008.
    1. Santilli V., Bernetti A., Mangone M., Paoloni M. Clinical definition of sarcopenia. Clin. Cases Miner. Bone Metab. 2014;11:177–180. doi: 10.11138/ccmbm/2014.11.3.177.
    1. Gori A.M., Corsi A.M., Fedi S., Gazzini A., Sofi F., Bartali B., Bandinelli S., Gensini G.F., Abbate R., Ferrucci L. A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am. J. Clin. Nutr. 2005;82:335–341. doi: 10.1093/ajcn/82.2.335.
    1. Škovierová H., Vidomanová E., Mahmood S., Sopková J., Drgová A., Červeňová T., Halašová E., Lehotský J. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int. J. Mol. Sci. 2016;17:1733. doi: 10.3390/ijms17101733.
    1. Ingenbleek Y. Lean body mass harbors sensing mechanisms that allow safeguarding of methionine homeostasis. Nutrients. 2017;9:1035. doi: 10.3390/nu9091035.
    1. Cruz-Jentoft A.J., Landi F., Schneider S.M., Zuniga C., Arai H., Boirie Y., Chen L.-K., Fielding R.A., Martin F.C., Michel J.-P., et al. Prevalence of and interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS) Age Ageing. 2014;43:748–759. doi: 10.1093/ageing/afu115.
    1. Friedman J., Lussiez A., Sullivan J., Wang S., Englesbe M. Implications of sarcopenia in major surgery. Nutr. Clin. Pract. 2015;30:175–179. doi: 10.1177/0884533615569888.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅